Sana Biotechnology, Inc. (SANA)
1.88
-0.14
(-6.93%)
USD |
NASDAQ |
Nov 16, 16:00
1.88
0.00 (0.00%)
After-Hours: 20:00
Sana Biotechnology Enterprise Value : 491.45M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 491.45M |
| November 13, 2026 | 533.38M |
| November 12, 2026 | 530.39M |
| November 11, 2026 | 614.25M |
| November 10, 2026 | 656.19M |
| November 09, 2026 | 666.67M |
| November 06, 2026 | 638.22M |
| November 05, 2026 | 629.23M |
| November 04, 2026 | 695.12M |
| November 03, 2026 | 659.18M |
| November 02, 2026 | 647.20M |
| October 30, 2026 | 698.12M |
| October 29, 2026 | 743.05M |
| October 28, 2026 | 716.09M |
| October 27, 2026 | 668.17M |
| October 26, 2026 | 635.22M |
| October 23, 2026 | 626.23M |
| October 22, 2026 | 638.22M |
| October 21, 2026 | 632.23M |
| October 20, 2026 | 635.22M |
| October 19, 2026 | 617.25M |
| October 16, 2026 | 608.26M |
| October 15, 2026 | 669.67M |
| October 14, 2026 | 626.23M |
| October 13, 2026 | 650.20M |
| Date | Value |
|---|---|
| October 12, 2026 | 713.10M |
| October 09, 2026 | 764.01M |
| October 08, 2026 | 764.01M |
| October 07, 2026 | 743.05M |
| October 06, 2026 | 752.03M |
| October 05, 2026 | 790.97M |
| October 02, 2026 | 793.97M |
| October 01, 2026 | 793.97M |
| September 30, 2026 | 801.45M |
| September 29, 2026 | 780.03M |
| September 28, 2026 | 786.02M |
| September 25, 2026 | 790.51M |
| September 24, 2026 | 795.00M |
| September 23, 2026 | 830.92M |
| September 22, 2026 | 905.74M |
| September 21, 2026 | 836.90M |
| September 18, 2026 | 836.90M |
| September 17, 2026 | 836.90M |
| September 16, 2026 | 783.03M |
| September 15, 2026 | 854.86M |
| September 14, 2026 | 866.83M |
| September 11, 2026 | 845.88M |
| September 10, 2026 | 833.91M |
| September 09, 2026 | 857.85M |
| September 08, 2026 | 941.66M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.139B |
| Twist Bioscience Corp. | 6.096B |
| Beam Therapeutics, Inc. | 1.366B |
| Revolution Medicines, Inc. | 33.65B |
| Prelude Therapeutics, Inc. | 137.86M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.40M |
| Total Expenses (Quarterly) | -20.40M |
| EPS Diluted (Quarterly) | 0.0661 |
| Earnings Yield | -28.34% |
| Normalized Earnings Yield | -30.37 |